CSIMarket
 

Aptinyx Inc   (NASDAQ: APTX)

Aptinyx Inc 's

Competitiveness




 

APTX Sales vs. its Competitors Q1 2023



Comparing the current results to its competitors, Aptinyx Inc reported Revenue decrease in the 1 quarter 2023 year on year by 0 %, slower than the combined decrease of the APTX's competitors by -9.75 %, recorded in the same quarter.

List of APTX Competitors





Revenue Growth Comparisons




Net Income Comparison


Aptinyx Inc , slower than the average decrease reported by the company's competitors of -55.51 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -55.51 %

<<  APTX Stock Performance Comparisons



*Market share is calculated based on total revenue.





Publicly Traded Peers of Aptinyx Inc




Ptc Therapeutics inc
Share Performance



-9.38%
This Year



Ptc Therapeutics inc
Profile

PTC Therapeutics Inc's business model revolves around the research, development, and commercialization of innovative treatments for rare and genetic diseases.

More about Ptc Therapeutics inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 5,738.512 mill. $ 827.110 mill. $ -186.727 mill.


Third Harmonic Bio Inc
Share Performance



-55.68%
One Year



Third Harmonic Bio Inc
Profile

Third Harmonic Bio Inc's business model centers around developing and commercializing innovative therapeutic solutions through the utilization of bioinformatics and genomics.

More about Third Harmonic Bio Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 241.654 mill. $ - mill. $ 53.447 mill.


Tiziana Life Sciences Ltd
Share Performance



-32.33%
This Quarter



Tiziana Life Sciences Ltd
Profile

Tiziana Life Sciences Ltd's business model focuses on the development and commercialization of innovative therapeutics in the field of immunology and oncology.

More about Tiziana Life Sciences Ltd's Market Share

Market Cap. Revenues TTM Net Income TTM
$ - mill. $ - mill. $ -18.431 mill.


Vertex Pharmaceuticals Inc
Share Performance



+35.79%
One Year



Vertex Pharmaceuticals Inc
Profile

Vertex Pharmaceuticals Incs business model centers on the research and development of innovative therapies, primarily targeting cystic fibrosis and other serious diseases. They emphasize collaboration with organizations, strategic partnerships, and robust investment in R&D to deliver transformative treatments to patients and enhance their quality of life.

More about Vertex Pharmaceuticals Inc's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 138,961.504 mill. $ 12,587.200 mill. $ 4,405.200 mill.


Ventyx Biosciences Inc
Share Performance



+784.18%
One Year



Ventyx Biosciences Inc
Profile

Ventyx Biosciences Inc is a biotechnology company that follows a research and development-focused business model. It aims to develop innovative biopharmaceutical products and therapeutic solutions by leveraging its expertise in various fields such as genetic engineering, drug discovery, and clinical trials. The company seeks to form strategic partnerships and licensing agreements to accelerate the commercialization of its products.

More about Ventyx Biosciences Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 996.118 mill. $ - mill. $ -106.607 mill.

111 more competitors available

Sign in to see all competitors

Sources: Aptinyx Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Aptinyx Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.